A Phase 1, Randomized, Open Label, Single Dose, 5-treatment, 5- Period Crossover Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release Pregabalin Tablet Formulations Administered Following an Evening Meal and the Immediate Release Formulation Administered Fasted.
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Pregabalin (Primary)
- Indications Epilepsy; Fibromyalgia; Generalised anxiety disorder; Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Apr 2012 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual initiation date changed from Jan 2012 to Mar 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.